 4D pharma PLC AIM:DDD, NASDAQ:LBPS said it had hit its primary efficacy target in a phase III trial of one of its lead assets in kidney cancer. MRx0518 was used in combination with KEYTRUDA, the Merck blockbuster, which is a part of a class of drugs called immune checkpoint inhibitors ICIs. 